Cargando…
Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites
Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. A...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409563/ https://www.ncbi.nlm.nih.gov/pubmed/30781383 http://dx.doi.org/10.3390/pharmaceutics11020082 |
_version_ | 1783402002770821120 |
---|---|
author | Anraku, Makoto Tabuchi, Ryo Goto, Miwa Iohara, Daisuke Mizukai, Yasuyuki Maezaki, Yuji Michihara, Akihiro Kadowaki, Daisuke Otagiri, Masaki Hirayama, Fumitoshi |
author_facet | Anraku, Makoto Tabuchi, Ryo Goto, Miwa Iohara, Daisuke Mizukai, Yasuyuki Maezaki, Yuji Michihara, Akihiro Kadowaki, Daisuke Otagiri, Masaki Hirayama, Fumitoshi |
author_sort | Anraku, Makoto |
collection | PubMed |
description | Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the A(L) type, indicating the formation of a 1:1 inclusion complex. The release of OLM from tablets composed of the SD-CS/SBE-β-CD composite was slow in media at both pH 1.2 and at 6.8. The in vitro slow release characteristics of the SD-CS/SBE-β-CD composite were reflected in the in vivo absorption of the drug after normal rats were given an oral administration of the preparation. Furthermore, the SD-CS/SBE-β-CD composite continuously increased the antihypertensive effect of OLM in hypertensive rats, compared with that of the drug itself. These results suggest that a simple mixing of SD-CS and SBE-β-CD can be potentially useful for the controlled release of a drug for the continuous treatments of hypertension. |
format | Online Article Text |
id | pubmed-6409563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64095632019-03-29 Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites Anraku, Makoto Tabuchi, Ryo Goto, Miwa Iohara, Daisuke Mizukai, Yasuyuki Maezaki, Yuji Michihara, Akihiro Kadowaki, Daisuke Otagiri, Masaki Hirayama, Fumitoshi Pharmaceutics Article Sustained-release olmesartan tablets (OLM) were prepared by the simple, direct compression of composites of anionic sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and cationic spray-dried chitosan (SD-CS), and were evaluated for use as a sustained release preparation for the treatment of hypertension. An investigation of the interaction between OLM and SBE-β-CD by the solubility method indicated that the phase diagram of the OLM/SBE-β-CD system was the A(L) type, indicating the formation of a 1:1 inclusion complex. The release of OLM from tablets composed of the SD-CS/SBE-β-CD composite was slow in media at both pH 1.2 and at 6.8. The in vitro slow release characteristics of the SD-CS/SBE-β-CD composite were reflected in the in vivo absorption of the drug after normal rats were given an oral administration of the preparation. Furthermore, the SD-CS/SBE-β-CD composite continuously increased the antihypertensive effect of OLM in hypertensive rats, compared with that of the drug itself. These results suggest that a simple mixing of SD-CS and SBE-β-CD can be potentially useful for the controlled release of a drug for the continuous treatments of hypertension. MDPI 2019-02-15 /pmc/articles/PMC6409563/ /pubmed/30781383 http://dx.doi.org/10.3390/pharmaceutics11020082 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anraku, Makoto Tabuchi, Ryo Goto, Miwa Iohara, Daisuke Mizukai, Yasuyuki Maezaki, Yuji Michihara, Akihiro Kadowaki, Daisuke Otagiri, Masaki Hirayama, Fumitoshi Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title | Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title_full | Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title_fullStr | Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title_full_unstemmed | Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title_short | Design and Evaluation of An Extended-Release Olmesartan Tablet Using Chitosan/Cyclodextrin Composites |
title_sort | design and evaluation of an extended-release olmesartan tablet using chitosan/cyclodextrin composites |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409563/ https://www.ncbi.nlm.nih.gov/pubmed/30781383 http://dx.doi.org/10.3390/pharmaceutics11020082 |
work_keys_str_mv | AT anrakumakoto designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT tabuchiryo designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT gotomiwa designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT ioharadaisuke designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT mizukaiyasuyuki designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT maezakiyuji designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT michiharaakihiro designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT kadowakidaisuke designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT otagirimasaki designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites AT hirayamafumitoshi designandevaluationofanextendedreleaseolmesartantabletusingchitosancyclodextrincomposites |